Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XARACOLL
- Development stage
- Approved
- Lead developer
- Innocoll
- Modality
- Small Molecules
- Administration
- Implantation
01
Overview
XARACOLL (bupivacaine collagen sponge) is a surgically implantable, bioresorbable drug-device combination product developed by Innocoll for the management of acute postoperative pain. It consists of a biodegradable collagen matrix derived from bovine tendons impregnated with bupivacaine hydrochloride, a local anesthetic. The implant is placed directly into the surgical site during surgery, where the collagen matrix naturally biodegrades over several days while providing a sustained release of bupivacaine. Bupivacaine acts by blocking voltage-gated sodium channels in local nerve tissues, thereby inhibiting the initiation and conduction of pain impulses. XARACOLL was FDA-approved in August 2020 for use in adults following open inguinal hernia repair to provide local analgesia for up to 24 hours.
- Brand names
- XARACOLL
- Other names
- Bupivacaine Collagen SpongeCollaRx Bupivacaine
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on XARACOLL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XARACOLL.